Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | CDK1 | P06493 | 1/20 | 0.38 |
| ▸ | CDK4 | P11802 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.34 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.34 |
| ▸ | TYMS | P04818 | 1/20 | 0.34 |
| ▸ | PNP | P00491 | 1/20 | 0.33 |
| ▸ | GART | P22102 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7841194 | 0.86 | KMT2A (0.40) | MAPK1NPSR1KMT2AHIF1AMAPT | |
| SCHEMBL9688605 | 0.85 | KMT2A (0.50) | MAPK1TSHRNPSR1KMT2AHIF1A | |
| SCHEMBL6217873 | 0.74 | HTT (0.33) | CDK1CDK2MAPTALDH1A1GAA | |
| SCHEMBL28428691 | 0.72 | KMT2A (0.40) | NPSR1KMT2AMEN1MAPTALDH1A1 | |
| SCHEMBL12957011 | 0.71 | MAPK1 (0.78) | MAPK1TSHRNPSR1KMT2AMEN1 | |
| SCHEMBL9700257 | 0.68 | KDM4E (0.44) | NPSR1MAPT | |
| SCHEMBL12040852 | 0.68 | MAPT (0.33) | MAPT | |
| SCHEMBL2566115 | 0.68 | MAPT (0.33) | MAPT | |
| SCHEMBL12395271 | 0.67 | KMT2A (0.31) | KMT2A | |
| SCHEMBL1002933 | 0.66 | MAPT (0.32) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090069349-A1 | DEUTERIUM-ENRICHED PEMETREXED | PROTIA, LLC (US) | 2009-03-12 | — | — | US | disclosed |
| US-20090069349-A1 | DEUTERIUM-ENRICHED PEMETREXED | PROTIA, LLC (US) | 2009-03-12 | — | — | US | disclosed |
| EP-0268377-B1 | GLUTAMIC ACID DERIVATIVES, PROCESSES AND INTERMEDIATES FOR THEIR PREPARATION AND PHARMACEUTICAL FORMULATIONS CONTAINING THEM | THE WELLCOME FOUNDATION LIMITED (GB) | 1992-03-18 | — | — | EP | disclosed |
| US-4940713-A | ANTITUMOR AGENTS | BURROUGHS WELLCOME CO. (US) | 1990-07-10 | — | — | US | disclosed |
| US-4880812-A | ANTITUMOR AGENTS | BURROUGHS WELLCOME CO. (US) | 1989-11-14 | — | — | US | disclosed |
| EP-0268377-A2 | Glutamic acid derivatives, processes and intermediates for their preparation and pharmaceutical formulations containing them | THE WELLCOME FOUNDATION LIMITED (GB) | 1988-05-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069349-A1 | DEUTERIUM-ENRICHED PEMETREXED | DCTD, SAMHD1, DPYD | MAPK1 3764/4885TSHR 3555/4885NPSR1 4674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.